| Drug General Information |
| Drug ID |
D00NSD
|
| Former ID |
DIB011598
|
| Drug Name |
XL-820
|
| Synonyms |
EXEL-9820
|
| Indication |
Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48]
|
Phase 2 |
[1]
|
|---|
| Company |
Exelixis
|
| Target and Pathway |
| Target(s) |
Alpha platelet-derived growth factor receptor |
Target Info |
Inhibitor |
[2]
|
|---|
| Mast/stem cell growth factor receptor |
Target Info |
Inhibitor |
[2]
|
| VEGF receptor |
Target Info |
Inhibitor |
[2]
|
| Beta platelet-derived growth factor receptor |
Target Info |
Inhibitor |
[2]
|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Calcium signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
Endocytosis
|
|
PI3K-Akt signaling pathway
|
|
Focal adhesion
|
|
Gap junction
|
|
Regulation of actin cytoskeleton
|
|
HTLV-I infection
|
|
Pathways in cancer
|
|
MicroRNAs in cancer
|
|
Glioma
|
|
Prostate cancer
|
|
Melanoma
|
|
Central carbon metabolism in cancer
|
|
Choline metabolism in cancerhsa04014:Ras signaling pathway
|
|
Hematopoietic cell lineage
|
|
Melanogenesis
|
|
Acute myeloid leukemia
|
|
Central carbon metabolism in cancerhsa04014:Ras signaling pathway
|
|
HIF-1 signaling pathway
|
|
Transcriptional misregulation in cancer
|
|
Rheumatoid arthritishsa04010:MAPK signaling pathway
|
|
Choline metabolism in cancer
|
|
NetPath Pathway
|
TGF_beta_Receptor Signaling PathwayNetPath_15:IL3 Signaling Pathway
|
|
IL4 Signaling Pathway
|
|
KitReceptor Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
PDGF signaling pathwayP00005:Angiogenesis
|
|
PDGF signaling pathway
|
|
Pathway Interaction Database
|
ATF-2 transcription factor network
|
|
PDGFR-alpha signaling pathway
|
|
PDGF receptor signaling networkcmyb_pathway:C-MYB transcription factor network
|
|
Signaling events mediated by Stem cell factor receptor (c-Kit)ptp1bpathway:Signaling events mediated by PTP1B
|
|
Beta3 integrin cell surface interactions
|
|
S1P3 pathway
|
|
Nectin adhesion pathway
|
|
Signaling events mediated by TCPTP
|
|
SHP2 signaling
|
|
S1P1 pathway
|
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
|
PDGFR-beta signaling pathway
|
|
Validated targets of C-MYC transcriptional repression
|
|
PDGF receptor signaling network
|
|
Reactome
|
PIP3 activates AKT signaling
|
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
|
RAF/MAP kinase cascadeR-HSA-1257604:PIP3 activates AKT signaling
|
|
Regulation of KIT signaling
|
|
RAF/MAP kinase cascade
|
|
WikiPathways
|
Regulation of Actin Cytoskeleton
|
|
Osteoblast Signaling
|
|
Focal Adhesion
|
|
Hair Follicle Development: Organogenesis (Part 2 of 3)
|
|
PIP3 activates AKT signaling
|
|
Cardiac Progenitor Differentiation
|
|
Integrated Pancreatic Cancer Pathway
|
|
Allograft Rejection
|
|
Signaling Pathways in Glioblastoma
|
|
Signaling by PDGF
|
|
AngiogenesisWP304:Kit receptor signaling pathway
|
|
Differentiation Pathway
|
|
Signaling by SCF-KIT
|
|
miR-targeted genes in muscle cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in epithelium - TarBaseWP51:Regulation of Actin Cytoskeleton
|
|
MAPK Signaling Pathway
|
|
PDGF Pathway
|
| References |
| REF 1 | ClinicalTrials.gov (NCT00570635) A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib. U.S. National Institutes of Health. |
|---|
| REF 2 | National Cancer Institute Drug Dictionary (drug id 452042). |
|---|
